Inhibikase Therapeutics Inc (IKT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inhibikase Therapeutics Inc (IKT) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.59 Million) by net assets ($72.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Inhibikase Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.
Inhibikase Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Inhibikase Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Inhibikase Therapeutics Inc (IKT) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Inhibikase Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhibikase Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quartzsea Acquisition Corporati
NASDAQ:QSEA
|
0.000x |
|
Eightco Holdings Inc.
NASDAQ:ORBS
|
-0.005x |
|
Excel Cell Electronic Co Ltd
TW:2483
|
0.031x |
|
Wam Active Ltd
AU:WAA
|
0.010x |
|
Solteam Electronics Co Ltd
TWO:3484
|
0.029x |
|
Macauto Industrial Co Ltd
TWO:9951
|
0.069x |
|
Odlewnie Polskie SA
WAR:ODL
|
0.063x |
|
Interactive Digital Technologies
TWO:6486
|
0.015x |
Annual Cash Flow Conversion Efficiency for Inhibikase Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Inhibikase Therapeutics Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Inhibikase Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $94.87 Million | $-19.15 Million | -0.202x | +87.75% |
| 2023-12-31 | $10.98 Million | $-18.09 Million | -1.647x | -99.72% |
| 2022-12-31 | $21.04 Million | $-17.35 Million | -0.825x | -121.63% |
| 2021-12-31 | $38.42 Million | $-14.30 Million | -0.372x | -222.43% |
| 2020-12-31 | $9.78 Million | $-1.13 Million | -0.115x | -253.20% |
| 2019-12-31 | $-4.49 Million | $-338.29K | 0.075x | +108.20% |
| 2018-12-31 | $-777.97K | $714.99K | -0.919x | -1147.82% |
| 2017-12-31 | $-1.44 Million | $-126.39K | 0.088x | +300.90% |
| 2016-12-31 | $-1.35 Million | $-29.57K | 0.022x | -- |
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a p… Read more